

**Amendments to the Claims**

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1-31. Previously cancelled

32-39. Presently cancelled

40. (New) A pharmaceutical composition comprising:

- a) 60 mg of 6-hydroxy-2-(4-hydroxy-phenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene hydrochloride, characterized in that the benzo[b]thiophene compound is in particulate form, said particles having a mean particle size of less than about 25 microns, at least about 90% of said particles have a size of less than about 50 microns;
- b) a surfactant; and
- c) a water-soluble diluent.

41. (New) The composition of claim 40 wherein said benzothiophene is crystalline and wherein said particles have a mean particle size of between about 5 and about 25 microns.

42. (New) The composition of claim 41 wherein said particles have a mean particle size of between about 5 and about 20 microns and at least 90% of said particles have a size of less than about 35 microns.

43. (New) The composition of Claim 41 wherein the surfactant is polysorbate 80.

44. (New) The composition of Claim 41 wherein the water-soluble diluent comprises lactose.

45. (New) The composition of claim 41 further comprising a hydrophilic binder.

46. (New) The composition of claim 45, wherein the hydrophilic binder is polyvinylpyrrolidone.
47. (New) The composition of claim 41 further comprising a lubricant.
48. (New) The composition of claim 47, wherein the lubricant comprises at least one of magnesium stearate and stearic acid.
49. (New) The composition of claim 41 comprising polyvinylpyrrolidone, polysorbate 80, lactose, cross-linked polyvinylpyrrolidone, and magnesium stearate.
50. (New) The composition of claim 41 further comprising a film coating.
51. (New) A method for preventing postmenopausal osteoporosis comprising prophylactically administering the composition of claim 41 to a postmenopausal woman in need thereof.